title: IL-4 and IL-13 Inhibition in Atopic Dermatitis.
abstract: Atopic dermatitis (AD) is a chronic, prevalent, multi-factorial condition that affects infants, children, and adults. Beyond topical therapy, a variety of systemic agents such as steroids, methotrexate, cyclosporine, azathioprine, mycophenoloic acid, and other agents are utilized to treat moderate to severe AD. However, these agents are associated with potential long term adverse events and organ toxicity. There is an unmet need for a safer, long-term systemic agent to adequately control moderate to severe AD. The role of the Th2 cytokines, IL-4 and IL-13, in AD has led to the development of biologic agents to treat AD. The aim of this article is to review the role of IL-4 and IL-13 in the pathogenesis of AD and discuss some of the clinical trial data that target and inhibit IL-4 and IL-13 in positively altering the course and outcome of AD.<BR /><BR /> <EM>J Drugs Dermatol</EM>. 2016;15(8):925-929.
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Matsunaga
authors.forename: Paul S
authors.initials: PS
authors.lastname: Yamauchi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000008:administration & dosage*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D018793:Interleukin-13 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D015847:Interleukin-4 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; C578095:IL13 protein, human; C508598:IL4 protein, human; D018793:Interleukin-13; D015847:Interleukin-4; C582203:dupilumab